The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells

Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in the ESR1 (estrogen receptor alpha (ERα)) gene ligand-binding domain (LBD) represent a recognized mechanism of acquired resistance. Antiestrogens with improved efficacy vers...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:eLife
المؤلفون الرئيسيون: Fanning, Sean W, Jeselsohn, Rinath, Dharmarajan, Venkatasubramanian, Mayne, Christopher G, Karimi, Mostafa, Buchwalter, Gilles, Houtman, René, Toy, Weiyi, Fowler, Colin E, Han, Ross, Lainé, Muriel, Carlson, Kathryn E, Martin, Teresa A, Nowak, Jason, Nwachukwu, Jerome C, Hosfield, David J, Chandarlapaty, Sarat, Tajkhorshid, Emad, Nettles, Kendall W, Griffin, Patrick R, Shen, Yang, Katzenellenbogen, John A, Brown, Myles, Greene, Geoffrey L
التنسيق: Artigo
اللغة:Inglês
منشور في: eLife Sciences Publications, Ltd 2018
الموضوعات:
Cancer Biology
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6335054/
https://ncbi.nlm.nih.gov/pubmed/30489256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.37161
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة